近日，中国保险行业协会反保险欺诈专业委员会常务委员工作会议在京召开。中国保险行业协会党 委委员、副秘书长马晓伟出席会议并作指导讲话，反保险欺诈专委会主任委员单位中国银保信有关负责 人作工作报告，中国人寿集团、人保财险、新华保险、平安产险等26家常委单位代表参加本次会议。 此次会议的召开，为2026年行业反保险欺诈工作明确了路径、凝聚了合力。下一步，中国保险行业 协会反保险欺诈专委会将持续联动各委员单位，以更务实的举措推进各项任务落地，为保险行业高质量 发展提供坚实保障。 责任编辑：杨喜亭 会议聚焦反保险欺诈领域"筑牢风险防线、凝聚行业合力"核心任务，全面总结反保险欺诈专委会以 往工作成效，研究部署2026年重点任务，审议并明确年度工作规划。马晓伟强调，反保险欺诈是保险业 践行"以人民为中心"发展思想的重要体现，专委会要以此次会议为契机，进一步发挥统筹协调作用：既 要聚焦技术创新破解反诈难题，也要强化协同机制凝聚行业力量；既要完善制度标准规范工作流程，也 要加强宣传教育营造反诈氛围，切实为保险行业转型升级注入安全动能。与会代表围绕反保险欺诈智能 化技术应用、跨机构线索共享机制、金融黑灰产治理等行业核心议题深入研 ...

Core Viewpoint - The meeting of the Life Insurance Rate Research Expert Advisory Committee highlighted a slight decrease in the predetermined interest rate for life insurance products to 1.89%, marking the fifth consecutive adjustment since the establishment of a dynamic adjustment mechanism linked to market rates [1][2]. Group 1: Rate Adjustments - The current predetermined interest rate for life insurance products is 1.89%, down from 1.90%, reflecting a continuous decline in recent adjustments [1]. - The historical adjustments for the predetermined interest rate were 2.34%, 2.13%, 1.99%, and 1.90% in the previous quarters, showing a decreasing trend with diminishing adjustment magnitudes [1]. - The downward adjustments have eased market concerns regarding the marginal decline of life insurance predetermined interest rates [1]. Group 2: Dynamic Adjustment Mechanism - The dynamic adjustment mechanism has been successfully implemented, enhancing cost efficiency, market-oriented levels, and risk management capabilities within the industry [2]. - The renaming of the committee to the Life Insurance Rate Research Expert Advisory Committee aligns better with the needs of liability research under new accounting standards [2]. - The meeting emphasized the positive outcomes of industry transformation, removing previous language about "facing challenges" [2]. Group 3: Product Stability - Current life insurance products, such as increasing whole life insurance, do not face delisting pressure as the predetermined interest rate remains within acceptable limits [3]. - Most insurance companies have a predetermined interest rate of 2.0%, which is only 11 basis points above the latest research value of 1.89%, not triggering the regulatory threshold for adjustment [3]. - The long-term bond yield trend is expected to stabilize, reducing the likelihood of new adjustments to the predetermined interest rate [3]. Group 4: Future Projections - The industry anticipates that the predetermined interest rate for life insurance products will maintain its current level, with low probability for significant fluctuations in 2026 [4]. - If the yield curve for government bonds and other interest rates remain stable, the projected predetermined interest rate for the end of 2026 is estimated to be 2.00%, consistent with current product offerings [4]. - Experts suggest that the downward adjustment of the predetermined interest rate is reaching a rational level, with limited room for further declines due to stabilizing asset returns [5].

步入2026年，保险资金积极探索服务科创企业的新思路、新方法，加大对前沿领域与新兴产业的支持力 度，展现出加快向"耐心资本+创新保单"双轮驱动模式演进的态势。 业内人士表示，在资金端，险资不断丰富"工具箱"，通过股、债、基、另类等工具，为集成电路、人工 智能、生物医药等赛道注入"耐心资本"，构建起全周期投融资支持体系。在产品端，科技保险持续迭 代，正在重新定义在培育新质生产力过程中的价值，保障链条从研发拓展至产业化全流程，针对人形机 器人、商业航天、低空经济、生成式AI等前沿场景，提供定制化"创新保单"，延展共保体机制，为企业 创新提供关键的风险"减震器"。 人保资产相关负责人表示，应加强专业赛道研究，赋能一级、二级市场科创投资。用好"股权基金+股 权计划"的投资模式，加强与优秀管理人、优质国企、产业龙头及政府平台合作，着力抓大项目、标杆 投新投未来 当前，在政策引导下，险资通过"直接+间接"方式覆盖科创企业投资，形成了包括股、债、基、另类等 工具在内的多元化投资布局，覆盖了人工智能、半导体、高端制造、新材料、新能源等诸多领域。业内 人士表示，通过多元工具矩阵，险资基本构建起从种子期、初创期、成长期到成熟期的 ...

Core Viewpoint - A fraudulent scheme involving "personal injury yellow cattle" in traffic accident claims has been uncovered, where individuals manipulated medical records and exaggerated injuries to obtain excessive insurance compensation, leading to the dismantling of this illegal industry chain [2][10]. Group 1: Fraudulent Activities - Individuals posing as legal representatives approached accident victims, offering to help them secure higher compensation, which led to the signing of agency agreements [4]. - The fraudulent activities included instructing victims to modify medical records and exaggerate their conditions, resulting in unjustified disability ratings [4][10]. - The scheme involved a network of individuals, including hospital staff and legal agents, who collaborated to exploit victims and insurance companies [10]. Group 2: Legal Proceedings and Investigations - The Zhejiang Provincial Procuratorate initiated a special supervision activity that uncovered multiple cases of fraudulent injury claims, leading to a thorough investigation [5]. - Evidence was gathered through meticulous examination of medical records, court documents, and insurance claims, revealing systemic fraud in disability assessments [5][6]. - A specialized task force was formed to analyze data and identify suspicious claims, resulting in the overturning of numerous fraudulent disability assessments [7][11]. Group 3: Outcomes and Reforms - The investigation led to the arrest of key individuals involved in the fraud, although they initially denied wrongdoing [8]. - The procuratorial authorities pursued both criminal charges and civil legal supervision, resulting in the annulment of previous court decisions and the reassessment of compensation amounts based on actual injuries [11]. - Recommendations were made to regulatory bodies to enhance oversight of the judicial appraisal industry and mitigate risks in insurance claims, aiming to establish a long-term mechanism to combat such fraudulent activities [11][12].

Group 1 - The core point of the article is that Swiss Re Life Insurance has increased its stake in Qingdao Beer (00168) by purchasing 200,000 shares at a price of HKD 49.9658 per share, totaling HKD 9.9932 million [1] - After the purchase, Swiss Re Life Insurance's total holdings in Qingdao Beer amount to approximately 39.374 million shares, representing a 6.01% ownership stake [1]

Group 1 - The CSI 300 Index consists of 300 representative securities from the Shanghai and Shenzhen markets, reflecting the overall performance of large-cap stocks and benefiting from China's steady economic growth and continuous industrial optimization [1][5][60] - As of December 31, 2025, the average market capitalization of CSI 300 constituents reached 225.49 billion, significantly higher than that of the CSI 500 and other indices, indicating a strong leader effect [7][60] - The top ten weighted stocks account for a total of 23.08% of the index, with an average total market capitalization of 942.8 billion, showcasing competitive leading enterprises across various sectors [10][60] Group 2 - The CSI 300 Index is the preferred choice for broad-based allocation, with its fund size reaching nearly 1.2 trillion, accounting for almost 50% of all broad-based index funds [12][61] - From 2015 to 2025, the index's industry structure underwent significant transformation, with traditional finance and real estate weights declining, while emerging industries like electronics and new energy surged [15][61] - The concentration of the top three industries decreased from 40.24% to 35.85%, reflecting a shift from real estate and finance-driven growth to technology and innovation-driven growth [15][61] Group 3 - The CSI 300 Index shows strong growth potential, with projected EPS growth rates of 3.76% for 2024, 5.43% for 2025, and 11.46% for 2026, alongside net profit growth rates of 2.78%, 9.67%, and 9.40% respectively [17][60] - The index's profitability has been steadily increasing, indicating robust growth capabilities [17][60] Group 4 - The Huian CSI 300 Index Enhanced A fund, managed by Liu Yucai since September 27, 2023, employs an innovative fundamental quantitative investment approach, aiming for long-term value enhancement while controlling tracking error [20][61] - Since the strategy adjustment to "tight constraints, low deviation" at the end of 2024, the fund achieved a cumulative excess return of 7.23% in 2025, ranking first among peers [39][62] - The fund maintained a high stock position between 90%-95% since 2025, demonstrating a commitment to active management [44][62] Group 5 - The fund's stock turnover rate is significantly lower than the average of its peers, indicating strong stock selection capabilities, with average quarterly returns of 0.66% in 2025 [63][62] - The fund's performance in 2025 included a relative maximum drawdown of only -0.57%, ranking second among peers, and an annualized tracking error of 1.28% [41][62]

日经225指数开盘下跌0.6%，报53023.88点，受汽车和保险类股拖累。韩国综合股价指数（KOSPI）开 盘上涨1.2%，报5145.39点。 责任编辑：王永生 日经225指数开盘下跌0.6%，报53023.88点，受汽车和保险类股拖累。韩国综合股价指数（KOSPI）开 盘上涨1.2%，报5145.39点。 责任编辑：王永生 ...

Core Viewpoint - The article discusses the ongoing efforts by the Trump administration to lower drug prices in the U.S., highlighting the strong pricing power of pharmaceutical companies and the complexities of the healthcare payment system, which includes private insurance and pharmacy benefit managers (PBMs) [2][35]. Summary by Sections U.S. Healthcare System Overview - The U.S. healthcare system is characterized by high medical service costs and low insurance coverage rates compared to other developed countries, with total healthcare spending reaching approximately $4.9 trillion in 2023, accounting for 17.6% of GDP [4][5]. - From 1960 to 2023, per capita national health expenditure in the U.S. increased from $146 to $14,570, a 99-fold increase with a compound annual growth rate of 7.6% [4]. Insurance Coverage and Efficiency - The U.S. insurance coverage rate is relatively low among developed nations, with 2023 coverage at 92.4%, lower than most OECD countries [9]. - The efficiency of healthcare services is also a concern, with the U.S. showing only an 8.8% decrease in all-cause mortality from 1999 to 2022, compared to a 25.9% decrease in the UK during the same period [7]. Medicare and Medicaid - Medicare, the primary public insurance program, covers approximately 65 million elderly and disabled individuals, while Medicaid covers about 91.7 million low-income individuals, with a compound annual growth rate of 7.0% in spending from 2013 to 2023 [18][19]. - Private insurance dominates the U.S. healthcare system, covering about 207 million people, or 62% of the population, with employer-sponsored plans being the most common [19]. PBM Role and Pricing Mechanisms - Pharmacy Benefit Managers (PBMs) play a crucial role in the drug supply chain, managing drug formularies and negotiating prices, but their profit mechanisms, including rebate retention and price differentials, contribute to high drug prices [26][28]. - The consolidation of PBMs has raised concerns about their influence on drug pricing and transparency, prompting regulatory scrutiny at both state and federal levels [30]. Drug Pricing Reforms - The Trump administration has initiated several measures to reduce drug prices, including the Inflation Reduction Act, which allows for direct price negotiations for Medicare-covered drugs [33][35]. - The administration's efforts include setting price caps on insulin and negotiating discounts with pharmaceutical companies, with significant reductions observed in negotiated drug prices [33][39]. Pharmaceutical Pricing Trends - According to ICER, the median list price of new drugs is projected to increase by 24% and the net price by 51% from 2022 to 2024, indicating the continued strong pricing power of pharmaceutical companies [2][40]. - The article concludes that the interplay of the healthcare payment system, PBM profit mechanisms, and pharmaceutical pricing power complicates the effectiveness of drug price reform initiatives [39][40].

华见早安之声 请各位听众升级为见闻最新版APP，以便成功收听以下音频。 市场概述 科技巨头财报前标普500五连阳、收创最高纪录，道指回落。医保巨头UnitedHealth跌近20%、领跌道指成分股。财报公布前，微软涨超2%、特斯拉跌1%； 增加240亿美元NAND制造投资的美光收涨超5%；和Meta签下光缆大单的康宁涨超15%。 美元创四年新低，跌超1%、创去年4月特朗普宣布关税以来最大四日跌幅。日元三日累计涨4%，欧元和英镑创2021年来新高，离岸人民币近三年来首次盘 中涨破6.94。比特币盘中涨超2%，重新站上8.9万美元。 美消费者信心逊色，美债收益率刷新日低。 原油反弹，受中东局势影响，尾盘一度涨超3%。黄金连续六日收创历史新高，现货黄金一度涨超3%。白银震荡。 亚洲时段，A股午后拉升，三大股指集体收涨，算力产业链爆发，恒指涨超1%，紫金黄金涨超11%，沪银逆势涨7%。 要闻 中国12月规模以上工业企业利润同比增长 5.3%，全年同比增长0.6%，实现四年来首次增长。 美国将在中东举行空军战备演习，油价盘中涨3%，现货黄金涨超2%。特朗普：若遭暗杀，将把伊朗"从地球上抹去"！ 美元跌至四年低谷，特朗普 ...

Company News - Shenwan Hongyuan (06806.HK) expects a net profit of approximately 9.1 to 10.1 billion yuan for 2025, representing a year-on-year increase of 74.64% to 93.83% [8] - China Overseas Property (02669.HK) anticipates a revenue increase of about 5% to 7% for the fiscal year 2025, while gross profit and net profit are expected to decline by approximately 3% to 4% and 9% to 10%, respectively, due to a slowdown in contract conversion speed in the real estate sector [8] - Minmetals Resources (01208.HK) expects its unaudited profits for the 2025 fiscal year to be negatively impacted by impairment expenses [8] - China Traditional Chinese Medicine (00570.HK) issued a profit warning, forecasting a net loss of approximately 350 to 500 million yuan for the 2025 fiscal year [8] - Emperor Watch and Jewellery (00887.HK) announced a profit increase, expecting a net profit of no less than 420 million HKD for the 2025 fiscal year, representing a year-on-year growth of over 60% [9] - Vanke Enterprises (02202.HK) plans to obtain a loan of up to 2.36 billion yuan from its major shareholder, Shenzhen Metro Group [10] Market Performance - The Nasdaq China Golden Dragon Index rose by 0.48%, with notable gains in popular Chinese concept stocks such as Kingsoft Cloud, which increased by 8.77%, and Bilibili, which rose by 3.43% [6] - The Hang Seng Index increased by 1.35%, closing at 27,126.95 points, while the Technology Index rose by 0.50% [6] - Market performance showed active interest in sectors such as insurance, semiconductors, and AI applications, while coal, internet healthcare, and pharmaceutical stocks faced downward pressure [7]